Evidence map›Paper›PMID 29620209›Full record

ArticleMolecular medicine reports2018

Epigallocatechingallate attenuates myocardial injury in a mouse model of heart failure through TGF‑β1/Smad3 signaling pathway.

Keyan Chen, Wei Chen, Shi Li Liu, Tian Shi Wu, Kai Feng Yu, Jing Qi, Yijun Wang, Hui Yao, Xiao Yang Huang, Ying Han and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect.Journal of cardiovascular development and disease · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Keyan ChenDepartment of Laboratory Animal Science, China Medical University, Shenyang, Liaoning 110122, P.R. China.
Wei ChenDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Shi Li LiuDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Tian Shi WuDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Kai Feng YuDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Jing QiDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Yijun WangDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Hui YaoDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Xiao Yang HuangDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Ying HanDepartment of Cardiology, Jinqiu Hospital of Liaoning Province, Shenyang, Liaoning 110016, P.R. China.
Ping HouDepartment of Cardiology, The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110032, P.R. China.
Liaoning University of Traditional Chinese Medicine · CNAffiliated Hospital of Liaoning University of Traditional Chinese Medicine · CNChina Medical University · CNShenyang Anorectal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to assess the protective effect of epigallocatechingallate (EGCG) against myocardial injury in a mouse model of heart failure and to determine the mechanism underlying regulation of the transforming growth factor‑β1/mothers against decapentaplegic homolog 3 (TGF‑β1/Smad3) signaling pathway. Mouse models of heart failure were established. Alterations in ejection fraction, left ventricular internal diastolic diameter (LVIDd) and left ventricular internal systolic diameter (LVIDs) were measured by echocardiography. Pathological alterations of myocardial tissue were determined by hematoxylin and eosin, and Masson staining. The levels of serum brain natriuretic peptide (BNP), N‑terminal‑proBNP, interleukin (IL)‑1β, IL‑6, tumor necrosis factor‑α, malondialdehyde, superoxide dismutase and glutathione peroxidase were detected with ELISA. Expression of collagen I, collagen III were detected by western blotting and reverse transcription quantitative polymerase chain reaction. Transforming growth factor‑β1 (TGF‑β1), Smad3, phosphorylated (p)‑Smad3, apoptosis regulator BAX (Bax), caspase‑3 and apoptosis regulator Bcl2 in mouse cardiac tissue were measured by western blotting. P‑smad3 and TGF‑β1 were measured by immunofluorescence staining. EGCG reversed the alterations in LVIDd and LVIDs induced by establishment of the model of heart failure, increased ejection fraction, inhibited myocardial fibrosis, attenuated the oxidative stress, inflammatory and cardiomyocyte apoptosis and lowered the expression levels of collagen I and collagen III. Following treatment with TGF‑β1 inhibitor, the protective effect of EGCG against heart failure was attenuated. The results of the present study demonstrated that EGCG can inhibit the progression and development of heart failure in mice through inhibition of myocardial fibrosis and reduction of ventricular collagen remodeling. This protective effect of EGCG is likely mediated through inhibition of TGF‑β1/smad3 signaling pathway.

Indexed as

AnimalsApoptosisBiomarkersCatechinCytokinesDisease Models, AnimalFibrosisHeart FailureInflammation MediatorsMaleMiceMyocardiumOxidative StressSignal TransductionSmad3 ProteinTransforming Growth Factor beta1BiomarkersCatechinCytokinesepigallocatechin gallateInflammation MediatorsSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor beta1

Identifiers

PMID29620209
PMCPMC5983962
OpenAlexW2794856367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.